Guizhou Sanli Pharmaceutical Co.,Ltd (SHA:603439)

Market Cap	5.45B +10.5%
Revenue (ttm)	1.68B -21.4%
Net Income	48.72M -81.3%
EPS	0.12 -81.4%
Shares Out	404.74M
PE Ratio	115.17
Forward PE	n/a
Dividend	0.06 (0.45%)
Ex-Dividend Date	Jun 30, 2026

Volume	10,455,000
Open	13.33
Previous Close	13.43
Day's Range	13.33 - 13.79
52-Week Range	10.49 - 17.46
Beta	0.96
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHA:603439

Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonic, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, including sprays, granules, capsules, pills, tablets, medicated wines, and ointments. The company was founded in 1995 and is based in Anshun, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 1,887
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603439

Financial Performance

In 2025, SHA:603439's revenue was 1.70 billion, a decrease of -20.59% compared to the previous year's 2.14 billion. Earnings were 46.25 million, a decrease of -83.12%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error